406213-75-0 Usage
Uses
Used in Pharmaceutical Industry:
Tos-PEG7-t-butyl ester is used as a molecular linker for improving the solubility and stability of drug molecules. The hydrophilic PEG spacer enhances the aqueous solubility of the drug, while the t-butyl ester and tosyl group facilitate chemical modifications and conjugations, leading to improved pharmacokinetic properties and therapeutic efficacy.
Used in Chemical Synthesis:
In the field of chemical synthesis, Tos-PEG7-t-butyl ester is used as a protecting group for carboxyl groups during the synthesis of complex molecules. The t-butyl group can be selectively deprotected under acidic conditions, allowing for further reactions to be carried out on the now-free carboxyl group.
Used in Bioconjugation:
Tos-PEG7-t-butyl ester is used as a bioconjugation agent for attaching biologically active molecules, such as peptides, proteins, or nucleic acids, to other molecules or surfaces. The PEG spacer provides a hydrophilic environment, reducing non-specific interactions and improving the stability of the conjugate. The tosyl group can be used for selective conjugation through nucleophilic substitution reactions.
Used in Drug Delivery Systems:
In drug delivery systems, Tos-PEG7-t-butyl ester is used as a component of prodrugs or drug carriers. The PEG spacer can improve the solubility and circulation time of the drug in the body, while the t-butyl ester and tosyl group can be used to control the release of the active drug through triggered deprotection mechanisms, such as pH-sensitive or enzyme-catalyzed processes.
Used in Materials Science:
In materials science, Tos-PEG7-t-butyl ester can be used to modify the surface properties of various materials, such as polymers, nanoparticles, or hydrogels. The PEG spacer can provide hydrophilicity, biocompatibility, and resistance to protein adsorption, while the t-butyl ester and tosyl group can be used for further functionalization or crosslinking of the material.
Check Digit Verification of cas no
The CAS Registry Mumber 406213-75-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,0,6,2,1 and 3 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 406213-75:
(8*4)+(7*0)+(6*6)+(5*2)+(4*1)+(3*3)+(2*7)+(1*5)=110
110 % 10 = 0
So 406213-75-0 is a valid CAS Registry Number.
406213-75-0Relevant academic research and scientific papers
Design, Synthesis, and Evaluation of WD-Repeat-Containing Protein 5 (WDR5) Degraders
D?lle, Anja,Adhikari, Bikash,Kr?mer, Andreas,Weckesser, Janik,Berner, Nicola,Berger, Lena-Marie,Diebold, Mathias,Szewczyk, Magdalena M.,Barsyte-Lovejoy, Dalia,Arrowsmith, Cheryl H.,Gebel, Jakob,L?hr, Frank,D?tsch, Volker,Eilers, Martin,Heinzlmeir, Stephanie,Kuster, Bernhard,Sotriffer, Christoph,Wolf, Elmar,Knapp, Stefan
, p. 10682 - 10710 (2021/05/29)
Histone H3K4 methylation serves as a post-translational hallmark of actively transcribed genes and is introduced by histone methyltransferase (HMT) and its regulatory scaffolding proteins. One of these is the WD-repeat-containing protein 5 (WDR5) that has also been associated with controlling long noncoding RNAs and transcription factors including MYC. The wide influence of dysfunctional HMT complexes and the typically upregulated MYC levels in diverse tumor types suggested WDR5 as an attractive drug target. Indeed, protein-protein interface inhibitors for two protein interaction interfaces on WDR5 have been developed. While such compounds only inhibit a subset of WDR5 interactions, chemically induced proteasomal degradation of WDR5 might represent an elegant way to target all oncogenic functions. This study presents the design, synthesis, and evaluation of two diverse WDR5 degrader series based on two WIN site binding scaffolds and shows that linker nature and length strongly influence degradation efficacy.
SPLICEOSTATIN ANALOGS
-
, (2014/05/24)
The present invention is directed to novel cytotoxic spliceostatin analogs (I) and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.
